48024
document
[ Effect of treatment of non-nephrotic syndrome IgA nephropathy with Shenyanning ] . OBJECTIVE To observe the curative effect of Shenyanning ( SYN ) on non-nephrotic syndrome IgA nephropathy ( IgAN ) . METHODS Seventy primary IgAN patients were equally randomized into two groups , the treatment group and the control group , they were orally treated with SYN Decoction ( one dose per day ) and Losartan ( 50 mg per day ) respectively for 1 year . Efficacy of treatment , Chinese medicine syndrome scores , end-point events occurrence as well as changes of related laboratory indices were observed . RESULTS The total effective rate in the treatment group was obviously higher than that in the control group ( 77.1 % vs. 54.3 % , P < 0.05 ) . After treatment , the Chinese medicine syndrome scores , urinary protein and urinary red-cell count reduced significantly in the treatment group ( P < 0.05 or P < 0.01 ) and showed significant difference as compared with those in the control group ( P < 0.05 or P < 0.01 ) ; while the endogenous creatinine clearance was changed insignificantly in both groups . Beside , the occurrence of end-point events in the treatment group was slightly lower than that in the control group , though showed no statistical difference between them . CONCLUSION The curative effect of SYN in treating IgAN was obviously better than that of simple Western medicine .
48025
Intervention_Pharmacological
Shenyanning
48026
Intervention_Pharmacological
Shenyanning ( SYN )
48027
Intervention_Pharmacological
SYN Decoction
48028
Intervention_Pharmacological
Losartan
48029
Outcome_Physical
curative effect
48030
Outcome_Other
Efficacy of treatment
48031
Outcome_Physical
Chinese medicine syndrome scores
48032
Outcome_Physical
end-point events occurrence
48033
Outcome_Physical
laboratory indices
48034
Outcome_Other
total effective rate
48035
Outcome_Physical
Chinese medicine syndrome scores
48036
Outcome_Physical
urinary protein
48037
Outcome_Physical
urinary red-cell count
48038
Outcome_Physical
endogenous creatinine clearance
48039
Outcome_Physical
end-point events
48040
Participant_Condition
non-nephrotic syndrome IgA nephropathy
48041
Participant_Condition
non-nephrotic syndrome IgA nephropathy ( IgAN )
48042
Participant_Sample-size
Seventy
48043
Participant_Condition
primary IgAN